For decades, some of cancer’s most important drivers were considered “undruggable” because they lacked the clear molecular features that traditional therapies rely on. These targets control essential cellular processes, allowing tumors to grow aggressively and resist treatment. Today, researchers are developing innovative strategies to strike back, turning previously “undruggable” targets into therapeutic vulnerabilities.
This infographic explores the biological challenges behind cancer’s toughest targets and examines the therapeutic approaches that are opening new paths forward, from targeted protein degradation and RNA-based therapies to allosteric modulation, covalent inhibition, and protein–protein interaction disruption.
Download this infographic to learn:
- Why major cancer-driving targets such as small GTPases, transcription factors, tumor suppressors, and intrinsically disordered proteins have historically resisted drug development
- How emerging therapeutic approaches are overcoming longstanding barriers to targeting difficult cancer pathways
- What the next generation of oncology tools reveals about the future of precision cancer therapy
